NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01544348,"A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL",https://clinicaltrials.gov/study/NCT01544348,,COMPLETED,Phase 1 study to evaluate the safety of MEDI4212.,YES,Allergic Asthma|Atopic Dermatitis|Allergic Rhinitis|Healthy Volunteers,OTHER: Placebo|BIOLOGICAL: Omalizumab|BIOLOGICAL: MEDI4212 5 mg Subcutaneous|BIOLOGICAL: MEDI4212 15 mg Subcutaneous|BIOLOGICAL: MEDI4212 60 mg Subcutaneous|BIOLOGICAL: MEDI4212 150 mg Subcutaneous|BIOLOGICAL: MEDI4212 300 mg Subcutaneous|BIOLOGICAL: MEDI4212 300 mg Intravenous,"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs), An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to Day 85 that were absent before treatment or that worsened relative to pre-treatment state., Day 1 to 85","Observed Serum Concentration, Serum concentration of omalizumab and MEDI4212 were measured for participants who received omalizumab and MEDI4212, respectively., Pre-dose and post-dose on Day 1; Day 2, 3, 5, 8, 15, 22, 29, 43, 57 and 85|Number of Participants Exhibiting Anti-Drug Antibodies for MEDI4212 at Any Visit, Anti-drug antibodies for MEDI4212 were analyzed for participants who received placebo or MEDI4212 as per planned analysis., Days 1 (pre-dose), 15, 43, and 85|Free Immunoglobulin E (IgE) Serum Concentration, Day -28 (Screening), -1, 1 (pre-dose), 2, 3, 5, 8, 15, 22, 29, 43, 57, and 85 for all groups; 2 hours post-dose on Day 1 for MEDI4212 300 mg Intravenous group only",,MedImmune LLC,,ALL,ADULT,PHASE1,295,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",CD-RI-MEDI4212-1085,2012-01,2013-06,2013-06,2012-03-05,2014-12-18,2014-12-30,"Research Site, Cypress, California, United States|Research Site, Glendale, California, United States|Research Site, Denver, Colorado, United States|Research Site, Miami, Florida, United States|Research Site, Baltimore, Maryland, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Madison, Wisconsin, United States",
